Lexicon Pharmaceuticals Bolsa (NASDAQ: LXRX)

Lexicon Pharmaceuticals

LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Some Speculative Stocks Can Pay Off

Small Cap

Markets

LWLG

LXRX

Una semana marcada por incertidumbres económicas reveló señales de fuerza en tres empresas de sectores clave como salud, energía e IA.

Estas 3 acciones small-cap suben hasta 60% y desafían temores de recesión e inflación persistente

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

Earnings

Press Releases

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Analyst Ratings

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

News

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Health Care

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

General

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Biotech

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Erasca

Gossamer Bio

Gyre Therapeutics

I-MAB

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Kodiak Sciences

Keros Therapeutics

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Monopar Therapeutics

Myriad Genetics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Regenxbio

Savara

Verastem

HC Wainwright & Co.

Citigroup

Piper Sandler

Leerink Partners

Comments

Lexicon Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL